Inclusion Criteria:

          -  Histological proof of colorectal cancer

          -  Initially unresectable metastases confined to the liver according to CT scan, obtained
             ≤3 weeks prior to registration. Unresectability should be confirmed by the liver
             expertpanel. Patients with small (≤ 1 cm) extrahepatic lesions that are not clearly
             suspicious of metastases are eligible

          -  Known mutation status of RAS and BRAF

          -  WHO performance status 0-1 (Karnofsky performance status ≥ 70)

          -  Age ≥ 18 years

          -  No contraindications for liver surgery

          -  In case of primary tumor in situ: tumor should be resectable

          -  In case of resected primary tumor: adequate recovery from surgery

          -  Adequate organ functions, as determined by normal bone marrow function (Hb ≥ 6.0
             mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L), renal
             function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft formula, ≥ 30
             ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases ≤ 5x ULN)

          -  Life expectancy > 12 weeks

          -  Expected adequacy of follow-up

          -  Written informed consent

        Exclusion Criteria:

          -  Extrahepatic metastases, with the exception of small (≤ 1 cm) extrahepatic lesions
             that are not clearly suspicious of metastases

          -  Unresectable primary tumor

          -  Serious comorbidity or any other condition preventing the safe administration of study
             treatment (including both systemic treatment and surgery)

          -  Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive
             heart failure, CVA) within 12 months before randomisation

          -  Uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3
             antihypertensive drugs

          -  Previous systemic treatment for metastatic disease; previous adjuvant treatment is
             allowed if completed ≥ 6 months prior to randomisation

          -  Previous surgery for metastatic disease

          -  Previous intolerance of study drugs in the adjuvant setting

          -  Pregnant or lactating women

          -  Second primary malignancy within the past 5 years with the exception of adequately
             treated in situ carcinoma of any organ or basal cell carcinoma of the skin, or second
             primary colorectal cancer.

          -  Any concomitant experimental treatment.